[Market Insight] Korea Ratings Downgrades Contentree Central and Megabox Credit Ratings to ‘D’
Credit Ratings for Commercial Paper and Electronic Short-Term Bonds Downgraded to D
“This follows the filing for corporate rehabilitation proceedings on the 14th”
[Edaily Marketin, Reporter Kim Yeon-seo] The credit ratings of Megabox Joongang and Contentre Joongang have plummeted to ‘D’. On the 15th, Korea Ratings announced that it was downgrading the credit ratings of Megabox and Contentre Joongang’s commercial paper and electronic short-term bonds from ‘B+ (Negative)’ to ‘D’. A ‘D’ rating indicates a state of default.
Korea Ratings stated, “This downgrade follows the filing of an application with the Seoul Bankruptcy Court on June 14, 2026, to initiate corporate rehabilitation proceedings, along with applications for the preservation of company assets and a comprehensive injunction.”
According to the Financial Supervisory Service’s electronic disclosure system, Contentre Central submitted an application to the Seoul Bankruptcy Court on the 14th, following a board resolution, requesting the initiation of rehabilitation proceedings, preservation of assets, and a comprehensive injunction. The company cited “normalizing management and preserving value as a going concern” as the reason for the application.
In response to Contentree Central’s application to commence rehabilitation proceedings, the Korea Exchange suspended trading of its shares effective today. Whether rehabilitation proceedings will be initiated will be determined following a review by the court.
Megabox Joongang, a major subsidiary of Contentre Joongang, also filed for the commencement of rehabilitation proceedings with the Seoul Bankruptcy Court on the same day. Megabox Joongang is a major subsidiary of Contentre Joongang that operates movie theater businesses.
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…